Rhine R. Shen

3.2k citations
40 papers · 1.0k indexed · h-index 15

Rhine R. Shen

36 papers receiving 996 citations

Peers

Rhine R. Shen
Comparison fields: 5 of 88
  • Cancer Research 308
  • Immunology 330
  • Oncology 337
  • Dermatology 98
  • Molecular Biology 491
Replace Viswanathan Muthusamy with:
Viswanathan Muthusamy United States
Michele Ceribelli United States
Enriqueta Riballo United Kingdom
André Filipe Vieira Portugal
Malgorzata Anna Zal United States
Natalia Arenas-Ramirez Switzerland
Ruzanna Atoyan United States
Giuseppina Giglia‐Mari France
Christopher R. Zito United States
Melanie Cornejo United States
Rhine R. Shen relative to Viswanathan Muthusamy United States Viswanathan Muthusamy's profile →
Citations per field
00.5×1.5×2.0×
Viswanathan Muthusamy · 1×
Citations per year

Countries citing papers authored by Rhine R. Shen

Since Specialization
Citations

This map shows the geographic impact of Rhine R. Shen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rhine R. Shen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rhine R. Shen more than expected).

Fields of papers citing papers by Rhine R. Shen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rhine R. Shen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rhine R. Shen. The network helps show where Rhine R. Shen may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Rhine R. Shen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Rhine R. Shen Line = papers co-authored together Rhine R. Shen links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20250
2 202413
3 20241
4 20241
5 20242
6 20240
7 202318
8 202316
9 20232
10 20231
11 20201
12 201429
13 201357
14 201351
15 201167
16 2009184
17 200734
18 200613
19 200322
20 200230

About Rhine R. Shen

Rhine R. Shen is a scholar working on Oncology, Pathology and Forensic Medicine and Cancer Research, having authored 40 papers that have together received 1.0k indexed citations. Recurring topics across this work include CAR-T cell therapy research (24 papers), Lymphoma Diagnosis and Treatment (9 papers), Chronic Lymphocytic Leukemia Research (5 papers), NF-κB Signaling Pathways (5 papers), interferon and immune responses (4 papers), Virus-based gene therapy research (3 papers), Viral Infectious Diseases and Gene Expression in Insects (3 papers) and Epigenetics and DNA Methylation (3 papers). The work is most often cited by research in Cancer Research (308 citations), Immunology (330 citations) and Oncology (337 citations). Rhine R. Shen has collaborated with scholars based in United States, Netherlands and France. Frequent co-authors include William C. Hahn, Michael A. Teitell, Alicia Y. Zhou, Marco Herling, L. Jeffrey Medeiros, Dan Jones, Jessica E. Hutti, Lewis C. Cantley, Derek W. Abbott and John M. Asara. Their work appears in journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026